Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Two massive galaxies are bending light from the same distant quasar, creating a so-called Einstein zigzag lens that could ...